CA3234214A1 - Methods for determining mutations for increasing modified replicable rna function and related compositions and their use - Google Patents

Methods for determining mutations for increasing modified replicable rna function and related compositions and their use Download PDF

Info

Publication number
CA3234214A1
CA3234214A1 CA3234214A CA3234214A CA3234214A1 CA 3234214 A1 CA3234214 A1 CA 3234214A1 CA 3234214 A CA3234214 A CA 3234214A CA 3234214 A CA3234214 A CA 3234214A CA 3234214 A1 CA3234214 A1 CA 3234214A1
Authority
CA
Canada
Prior art keywords
rrna
rna
modified
sequence
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3234214A
Other languages
English (en)
French (fr)
Inventor
Tim Beissert
Mario Perkovic
Stefanie GAWLETTA
Patrick SORN
Silke Brill
Evelin NETT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
BioNTech SE
Original Assignee
Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz, BioNTech SE filed Critical Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Publication of CA3234214A1 publication Critical patent/CA3234214A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA3234214A 2021-10-18 2022-10-17 Methods for determining mutations for increasing modified replicable rna function and related compositions and their use Pending CA3234214A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2021078828 2021-10-18
EPPCT/EP2021/078828 2021-10-18
PCT/EP2022/078869 WO2023066874A1 (en) 2021-10-18 2022-10-17 Methods for determining mutations for increasing modified replicable rna function and related compositions and their use

Publications (1)

Publication Number Publication Date
CA3234214A1 true CA3234214A1 (en) 2023-04-27

Family

ID=78483247

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3234214A Pending CA3234214A1 (en) 2021-10-18 2022-10-17 Methods for determining mutations for increasing modified replicable rna function and related compositions and their use

Country Status (7)

Country Link
US (1) US20250250626A1 (cg-RX-API-DMAC7.html)
EP (1) EP4419708A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024539089A (cg-RX-API-DMAC7.html)
CN (1) CN118451194A (cg-RX-API-DMAC7.html)
AU (1) AU2022372325A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234214A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023066874A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025129137A1 (en) * 2023-12-14 2025-06-19 Amplitude Therapeutics, Inc. Two-component platform for trans amplifying rna (tarna) vaccination

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4522754A1 (en) * 2022-05-12 2025-03-19 Sunvax MRNA Therapeutics Inc. Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator
WO2025040709A1 (en) 2023-08-24 2025-02-27 BioNTech SE Systems and compositions comprising highly active trans-amplifying replicases
CN122514603A (zh) * 2023-11-02 2026-08-04 安普利特治疗公司 包含经化学修饰的核碱基的反式扩增rna
CN120379688A (zh) * 2024-01-24 2025-07-25 南京金斯瑞生物科技有限公司 一种自复制rna及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119827A1 (en) 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs
US8153773B2 (en) 2007-06-19 2012-04-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap
CN101848936B (zh) 2007-08-20 2017-05-03 葛兰素集团有限公司 生产方法
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
EP2451475A2 (en) * 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
EP3542789A3 (en) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするrnaの送達のためのpeg化リポソーム
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
AU2018333530B2 (en) * 2017-09-13 2024-05-30 Biontech Cell & Gene Therapies Gmbh RNA replicon for expressing a T cell receptor or an artificial T cell receptor
WO2020146690A1 (en) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Methods for in vitro evolution of rna replicons
JP2023521662A (ja) * 2020-04-03 2023-05-25 グリットストーン バイオ インコーポレイテッド 感染症抗原及びワクチン

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025129137A1 (en) * 2023-12-14 2025-06-19 Amplitude Therapeutics, Inc. Two-component platform for trans amplifying rna (tarna) vaccination

Also Published As

Publication number Publication date
WO2023066874A1 (en) 2023-04-27
EP4419708A1 (en) 2024-08-28
AU2022372325A1 (en) 2024-05-02
JP2024539089A (ja) 2024-10-28
CN118451194A (zh) 2024-08-06
US20250250626A1 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
RU2748892C2 (ru) Рнк-репликон для универсальной и эффективной генной экспрессии
RU2752580C2 (ru) Транс-реплицирующая рнк
US20250250626A1 (en) Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
JP7769644B2 (ja) 多用途かつ効率的な遺伝子発現のためのrnaレプリコン
US20250281602A1 (en) Replicon Compositions and Methods of Using Same for the Treatment of Diseases
US20250236883A1 (en) Modified replicable rna and related compositions and their use
WO2025040709A1 (en) Systems and compositions comprising highly active trans-amplifying replicases
HK40094277A (en) Rna replicon for versatile and efficient gene expression
HK40059264A (en) Trans-replicating rna
HK40023272A (en) Rna replicon for versatile and efficient gene expression
HK40023272B (en) Rna replicon for versatile and efficient gene expression
HK1259449B (en) Rna replicon for versatile and efficient gene expression

Legal Events

Date Code Title Description
P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20240918

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250925

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250925